Therapeutic Bacteria

Biologics are the pharmaceuticals of the future. Instead of by chemical synthesis, they are produced in living organisms such as bacterial cells. Wacker Biotech’s technology turns bacteria into tiny pharmaceutical factories producing large quantities of extraordinarily high-quality actives at acceptable prices. This unique science is in demand among pharmaceutical companies the world over. The market for biologics is growing, and Wacker Biotech is growing right along with it.

Mar 03, 2020

Presspicture

Wacker Biotech Amsterdam

Wacker Biotech Amsterdam

Through its 2018 acquisition of SynCo Bio Partners B.V. in Amsterdam, the Netherlands, Wacker Chemie AG strengthened its pharmaceutical protein business and expanded its portfolio – an important step to keep pace with the rapidly growing biologics market. As a result, Wacker Biotech now has three sites: Jena, Halle and Amsterdam, with a total of about 330 employees. (Photo: Wacker Chemie AG)

Order photo
Wacker Biotech Dr. Susanne Leonhartsberger

Wacker Biotech Dr. Susanne Leonhartsberger

Dr. Susanne Leonhartsberger has been the managing director of Wacker Biotech GmbH since 2017, and, in her capacity as the head of the Biopharmaceuticals business line, is responsible for WACKER’s biologics business. “What especially motivates me is that we’re providing innovative medications for sick people all over the world – and that’s how most of us feel,” the biologist observes. (Photo: Wacker Chemie AG)

Order photo
Wacker Biotech Fermenter

Wacker Biotech Fermenter

Production at Wacker Biotech GmbH: the Munich-based WACKER Group entered the field of contract manufacturing for pharmaceutical proteins when it acquired Prothera GmbH and subsequently renamed it Wacker Biotech in 2005. (Photo: Wacker Chemie AG)

Order photo
Wacker Biotech Lab

Wacker Biotech Lab

Specialists in the field of microbial production: Wacker Biotech GmbH is a full-service contract manufacturer of biologics with more than 20 years of experience with microbial systems. The company’s core competencies include the manufacture of active pharmaceutical ingredients, vaccines and live bacteria. (Photo: Wacker Chemie AG)

Order photo

Contact

contact image

Wacker Chemie AG
Media Relations & Information
Manuela Dollinger

Tel. +49 89 6279-1629
Send message